Current Report Filing (8-k)
September 11 2017 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section
13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): September
11, 2017
Repros
Therapeutics Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-15281
|
76-0233274
|
(State or other jurisdiction
of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal executive
offices and zip code)
|
|
(281) 719-3400
(Registrant’s telephone number,
including area code)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 7.01
|
Regulation FD Disclosure.
|
The information in
this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder,
the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report
shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.
Representatives of
Repros Therapeutics Inc., a Delaware corporation (the “Company”) are presenting updates on the Company’s Proellex®
and Enclomiphene clinical programs to various investors and other interested parties September 11 through September 13, 2017, in
New York, NY, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. These slides
contain statements that are “forward-looking statements” subject to the cautionary statement about forward-looking
statements set forth therein.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
Exhibit
Number
|
Description
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934 the Company has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Repros
Therapeutics Inc.
|
|
|
|
|
|
|
|
Date: September 11, 2017
|
By:
|
/s/ Kathi Anderson
|
|
|
|
Kathi Anderson
Chief Financial Officer
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024